50% of the tumor cells favored serous carcinoma. PTEN expression significantly differed in mucinous and serous carcinomas as well as in endometrioid carcinoma and borderline endometrioid tumor. There was significantly decreased β-catenin expression in the carcinomas compared with borderline tumors. In all of the different subtypes of ovarian carcinomas, we observed a significant association with decreased β-catenin expression to tumor grade as well as in serous carcinomas with increased nuclear grade, mitosis, and tumor grade. There was no significant relation between expressions of p53, PTEN, and β-catenin in epithelial ovarian tumors to FIGO staging, response to chemotherapy, serum CA- 125 marker, and tumor recurrence.Conclusion: p53 and PTEN are helpful in differentiation of some epithelial ovarian tumor subtypes. In serous carcinomas, diminished expression of β-catenin is associated with higher tumor and nuclear grade. This expression is significantly different in borderline and carcinomas.]]>
p. 135−142
2008-6687
Vol.6/No.3
10%-50%), and AR-highly (>50%) positive.Results: Among 49 patients with breast cancer, 34% were AR-positive and 44% of ERpositive and 22% of ER negative patients were AR-positive. There was no significant association between mean of testosterone and AR, ER, PR and HER2. AR was positive more frequently but not significantly statistically in older patients and patients less than 45 years of age. Testosterone level was higher in ER positive patients than ER negative and lower in AR positive patients than AR negative patients, but these findings were not statistically significant. ten persent of breast cancers were triple negative and AR was negative in all of them.Conclusion: Androgens and AR have role in pathophysiology of breast cancer and in the future one can use the potency of this pathway for the treatment of breast cancer.]]>
p. 143−150
2008-6687
Vol.6/No.3
p. 151−156
2008-6687
Vol.6/No.3
p. 157−164
2008-6687
Vol.6/No.3
p. 165−170
2008-6687
Vol.6/No.3
p. 171−177
2008-6687
Vol.6/No.3
p. 179−187
2008-6687
Vol.6/No.3
p. 189−193
2008-6687
Vol.6/No.3
p. 195−198
2008-6687
Vol.6/No.3
p. 199−200
2008-6687
Vol.6/No.3
p. 201−201
2008-6687
Vol.6/No.3